Pharmigene’s Genetic Test for Carbamazepine Response Now Standard in 50 Taiwan Hospitals

Pharmigene said last week that 50 hospitals in Taiwan will now administer its test for HLA-B*1502, which is a marker for increased risk of adverse events in Asian populations treated with the anti-seizure drug carbamazepine.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.